Patients: 404 people receiving donepezil treatment for moderate to severe Alzheimer's disease (minimum age 50 years; 5-10 mg/day donepezil; MMSE score 5-14), living in the community with a caregiver willing to participate in the study. Exclusions: B12 or folate deficiency, ischaemia, or other major physical or mental disease. 
MAIN RESULTS
At 24 weeks, memantine significantly improved cognition (SIB, p,0.001) and function (ADCS-ADL 19 , p = 0.03), compared with placebo (see http://www.ebmentalhealth.com/supplemental for table). Memantine improved overall clinical response (CIBC-Plus, p = 0.03) and reduced behavioural disturbances and psychiatric symptoms (NPI, p = 0.002), compared with placebo. Increased need for care was also significantly improved (BGP, p = 0.001). Memantine was generally safe and well tolerated (adverse events: 78% memantine v 72% placebo), however confusion and headache occurred in at least 5% of the memantine group (confusion: 7.9% memantine v 2.0% placebo, p = 0.01; headache: 6.4% memantine v 2.5% placebo, p = 0.09). More people receiving placebo discontinued the trial (12.4% placebo v 7.4% memantine).
CONCLUSIONS
Memantine significantly improves physical and mental health in people with severe to moderate Alzheimer's taking donepezil. 
Commentary

M
any patients with Alzheimer's disease (AD) take cholinesterase inhibitors (ChEIs), but early studies of memantine necessarily excluded such patients. This important study is the largest RCT of memantine and is the first to assess combination with cholinesterase inhibitors (ChEIs).
Important questions remain. Does memantine slow the rate of disease progression or, like the ChEIs, give a symptomatic boost? (The randomised follow up was too short to reveal whether the memantine and placebo groups were diverging.) Does memantine affect institutionalisation and/or mortality? Both are questions with significant pharmacoeconomic implications but inevitably not addressed in licensing studies. What are predictors of treatment response?
The key question is whether the beneficial effect seen in clinical trials is apparent in practice. The usual biases might have enhanced the effect size but two effects might have reduced it: the lower dropout rate in the memantine group and the ''noise'' of patients at varying points in their response to donepezil. Furthermore, the clinical global measure is significantly different between drug and placebo. Arguably this means that, by definition, there is a clinically significant effect.
So, would I prescribe memantine? Yes, in moderate and severe AD. Small changes in ADLs, care dependency, and behavioural disturbances in this patient group are more likely to have important repercussions on care needs than, for example, in mild disease. Experience with ChEIs suggests that even when changes in other measures are small, the clinical global measure should not be ignored.
Memantine does not seem to cause the early improvement in ADLs often seen on initiating ChEIs. This makes it difficult to make decisions about prolonged and continued treatment based on an initial assessment of treatment response. However, this strategy, although mandated for ChEIs by NICE in the UK, never had any evidence to support it: treatment response at 3 months does not predict reponse at 6 months. Once again, it looks as if stopping the drug will be more difficult than starting it. Perhaps we should stop worrying about this and start to accept that, as with other chronic diseases, long term treatment will be the norm in AD too. 
